Ryan Rader is an Oncology physician. OpenAlex indexes 42 publications with 833 citations (h-index 15).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4881 NE Goodview Cir
Lees Summit, MO 640641996
Telephone
913-588-1227Provider last certified this registry record 25 Jul 2023.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- Myriad Genetic Laboratories, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
64.3%Aromatase Inhibitor51.8%Anastrozole66%Letrozole26%Exemestane8%Part D≥100 patientsKinase inhibitor7.1%Verzenio53%Ibrance24%Kisqali24%Part D<11 patients+ 1 more class in this area
Nervous system
18%Opioid Agonist8.2%Oxycodone Hcl47%Morphine Sulfate Er31%Oxycodone-Acetaminophen22%Part D<11 patientsGabapentinoids4.9%Gabapentin100%Part D≥15 patients+ 3 more classes in this area
Metabolism & gastrointestinal
8.2%Serotonin-3 Receptor Antagonist4.2%Ondansetron Hcl100%Part D≥17 patientsPotassium supplement2.6%Potassium Chloride100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Case of Tumor-to-Tumor Metastasis: Breast Carcinoma Metastatic to Oncocytic Carcinoma of Thyroid
Kansas Journal of Medicine
2025 - Moving Beyond Cardiotoxicity Detection to Prevention: A Pharmacologic Review
Current Treatment Options in Cardiovascular Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”